RxDoctor Payments Data

James Spears, MD

Cardiovascular Disease · Dearborn, MINPI 1770520264

Payments from drug & device makers

$4,006in general payments, 2019–2025

Across 59 payments — averaging $67.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • ZOLL Circulation Inc$709
  • AstraZeneca$478
  • Abbott$337
  • Cardiva Medical, Inc.$231
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$177
  • plus $666 from 8 others

What the payments were for

  • Food & beverage$4,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,006 in reported general payments places this provider in the 50th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$54,470
Medicare patients
191
Services billed
592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$71,116
EntrestoSacubitril/Valsartan25$22,170
Repatha SureclickEvolocumab11$14,105
Atorvastatin Calcium48$935
Valsartan11$664
Doxazosin Mesylate12$484
Losartan Potassium35$454
Carvedilol23$403
Digoxin15$394
ClopidogrelClopidogrel Bisulfate25$367
Rosuvastatin Calcium16$250
Metoprolol Succinate16$245
Metoprolol Tartrate31$230
Nitroglycerin17$208
Pravastatin Sodium12$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$125$22,17025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →